Thrombotic thrombocytopenic purpura epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Sogand (talk | contribs)
4,941 edits
Sogand (talk | contribs)
4,941 edits
Line 11: Line 11:


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence of TTP is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Line 20: Line 20:


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may developTTP.  
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*The incidence of TTP increases with age; the median age at diagnosis is 40 years. TTP often occurs after 40 years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*TTP usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Females are more commonly affected by TTP than men. The females to men ratio is approximately 2 to 1.<ref name="pmid23729372">{{cite journal |vauthors=Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN |title=Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features |journal=Pediatr Blood Cancer |volume=60 |issue=10 |pages=1676–82 |date=October 2013 |pmid=23729372 |doi=10.1002/pbc.24612 |url=}}</ref>
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*The majority of TTP cases are reported in [geographical region].


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Revision as of 17:56, 27 September 2018

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura epidemiology and demographics

CDC on Thrombotic thrombocytopenic purpura epidemiology and demographics

Thrombotic thrombocytopenic purpura epidemiology and demographics in the news

Blogs on Thrombotic thrombocytopenic purpura epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of acuired TTP is about 0.3 per 100,000 adult per year.[1]
  • Data suggests the increased risk of TTP in black race and femal sex.[2]

Prevalence

  • The incidence of TTP is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may developTTP.
  • The incidence of TTP increases with age; the median age at diagnosis is 40 years. TTP often occurs after 40 years.

Race

  • TTP usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • Females are more commonly affected by TTP than men. The females to men ratio is approximately 2 to 1.[3]

Region

  • The majority of TTP cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].


References

  1. ↑ Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.
  2. ↑ Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7. doi:10.1002/ajh.21833. PMC 3420337. PMID 20799358.
  3. ↑ Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.

Template:WH Template:WS


Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Retrieved from "https://www.wikidoc.org/index.php?title=Thrombotic_thrombocytopenic_purpura_epidemiology_and_demographics&oldid=1495702"